Literature DB >> 24933342

Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

Jinhu Xiong1, Marilina Piemontese1, Jeff D Thostenson2, Robert S Weinstein1, Stavros C Manolagas1, Charles A O'Brien3.   

Abstract

Parathyroid hormone (PTH) excess stimulates bone resorption. This effect is associated with increased expression of the osteoclastogenic cytokine receptor activator of nuclear factor κB ligand (RANKL) in bone. However, several different cell types, including bone marrow stromal cells, osteocytes, and T lymphocytes, express both RANKL and the PTH receptor and it is unclear whether RANKL expression by any of these cell types is required for PTH-induced bone loss. Here we have used mice lacking the RANKL gene in osteocytes to determine whether RANKL produced by this cell type is required for the bone loss caused by secondary hyperparathyroidism induced by dietary calcium deficiency in adult mice. Thirty days of dietary calcium deficiency caused bone loss in control mice, but this effect was blunted in mice lacking RANKL in osteocytes. The increase in RANKL expression in bone and the increase in osteoclast number caused by dietary calcium deficiency were also blunted in mice lacking RANKL in osteocytes. These results demonstrate that RANKL produced by osteocytes contributes to the increased bone resorption and the bone loss caused by secondary hyperparathyroidism, strengthening the evidence that osteocytes are an important target cell for hormonal control of bone remodeling. Published by Elsevier Inc.

Entities:  

Keywords:  Osteoclast; Osteocyte; Parathyroid hormone; RANKL

Mesh:

Substances:

Year:  2014        PMID: 24933342      PMCID: PMC4125539          DOI: 10.1016/j.bone.2014.06.006

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  47 in total

1.  Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses.

Authors:  William F Powell; Kevin J Barry; Irena Tulum; Tatsuya Kobayashi; Stephen E Harris; F Richard Bringhurst; Paola Divieti Pajevic
Journal:  J Endocrinol       Date:  2011-01-10       Impact factor: 4.286

2.  The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice.

Authors:  Melda Onal; Carlo Galli; Qiang Fu; Jinhu Xiong; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Mol Endocrinol       Date:  2011-12-29

3.  Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss.

Authors:  Melda Onal; Jinhu Xiong; Xinrong Chen; Jeff D Thostenson; Maria Almeida; Stavros C Manolagas; Charles A O'Brien
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

4.  Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization.

Authors:  Liesbet Lieben; Ritsuko Masuyama; Sophie Torrekens; Riet Van Looveren; Jan Schrooten; Pieter Baatsen; Marie-Hélène Lafage-Proust; Tom Dresselaers; Jian Q Feng; Lynda F Bonewald; Mark B Meyer; J Wesley Pike; Roger Bouillon; Geert Carmeliet
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

Review 5.  In vitro and in vivo approaches to study osteocyte biology.

Authors:  Ivo Kalajzic; Brya G Matthews; Elena Torreggiani; Marie A Harris; Paola Divieti Pajevic; Stephen E Harris
Journal:  Bone       Date:  2012-10-13       Impact factor: 4.398

6.  Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.

Authors:  Vaibhav Saini; Dean A Marengi; Kevin J Barry; Keertik S Fulzele; Erica Heiden; Xiaolong Liu; Christopher Dedic; Akira Maeda; Sutada Lotinun; Roland Baron; Paola Divieti Pajevic
Journal:  J Biol Chem       Date:  2013-06-02       Impact factor: 5.157

7.  Suppression of autophagy in osteocytes mimics skeletal aging.

Authors:  Melda Onal; Marilina Piemontese; Jinhu Xiong; Yiying Wang; Li Han; Shiqiao Ye; Masaaki Komatsu; Martin Selig; Robert S Weinstein; Haibo Zhao; Robert L Jilka; Maria Almeida; Stavros C Manolagas; Charles A O'Brien
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

8.  Evidence for osteocyte regulation of bone homeostasis through RANKL expression.

Authors:  Tomoki Nakashima; Mikihito Hayashi; Takanobu Fukunaga; Kosaku Kurata; Masatsugu Oh-Hora; Jian Q Feng; Lynda F Bonewald; Tatsuhiko Kodama; Anton Wutz; Erwin F Wagner; Josef M Penninger; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

Review 9.  The amazing osteocyte.

Authors:  Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

10.  Matrix-embedded cells control osteoclast formation.

Authors:  Jinhu Xiong; Melda Onal; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

View more
  46 in total

Review 1.  Reproduction and breast cancer risk.

Authors:  Volker Hanf; Dorothea Hanf
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

2.  The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation.

Authors:  Jinhu Xiong; Maria Almeida; Charles A O'Brien
Journal:  Bone       Date:  2018-04-04       Impact factor: 4.398

3.  MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Authors:  Jesus Delgado-Calle; Benjamin Hancock; Elive F Likine; Amy Y Sato; Kevin McAndrews; Carolina Sanudo; Angela Bruzzaniti; Jose A Riancho; James R Tonra; Teresita Bellido
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

4.  IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95.

Authors:  Hyunsoo Kim; Noriko Takegahara; Matthew C Walsh; Sarah A Middleton; Jiyeon Yu; Jumpei Shirakawa; Jun Ueda; Yoshitaka Fujihara; Masahito Ikawa; Masaru Ishii; Junhyong Kim; Yongwon Choi
Journal:  Bone Res       Date:  2020-02-10       Impact factor: 13.567

5.  A Novel Osteogenic Cell Line That Differentiates Into GFP-Tagged Osteocytes and Forms Mineral With a Bone-Like Lacunocanalicular Structure.

Authors:  Kun Wang; Lisa Le; Brad M Chun; LeAnn M Tiede-Lewis; Lora A Shiflett; Matthew Prideaux; Richard S Campos; Patricia A Veno; Yixia Xie; Vladimir Dusevich; Lynda F Bonewald; Sarah L Dallas
Journal:  J Bone Miner Res       Date:  2019-06-07       Impact factor: 6.741

Review 6.  Parathyroid Diseases and T Cells.

Authors:  M Neale Weitzmann; Roberto Pacifici
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

7.  RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice.

Authors:  Yuko Fujiwara; Marilina Piemontese; Yu Liu; Jeff D Thostenson; Jinhu Xiong; Charles A O'Brien
Journal:  J Biol Chem       Date:  2016-10-12       Impact factor: 5.157

Review 8.  Parathyroid hormone: anabolic and catabolic actions on the skeleton.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Curr Opin Pharmacol       Date:  2015-04-05       Impact factor: 5.547

9.  A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse.

Authors:  Melda Onal; Kathleen A Bishop; Hillary C St John; Allison L Danielson; Erin M Riley; Marilina Piemontese; Jinhu Xiong; Joseph J Goellner; Charles A O'Brien; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

10.  Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.

Authors:  Marilina Piemontese; Jinhu Xiong; Yuko Fujiwara; Jeff D Thostenson; Charles A O'Brien
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-07-26       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.